Structure–activity relationship of GSK-3β inhibitors: insight into drug design for Alzheimer's disease
RSC Medicinal Chemistry · 2026 · 17 (1) · 15-51
DOI: 10.1039/d5md00211g ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift RSC Medicinal Chemistry, 2026. Verfasst von G Rajamani und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research Raebareli New Transit Campus-Lucknow Uttar Pradesh Ind…. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 127 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Demenz
Abstract (Originalsprache)
Structure–activity relationships of GSK-3β inhibitors for Alzheimer's disease.
Autor:innen und Institutionen
- Department of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research Raebareli New Transit Campus-Lucknow Uttar Pradesh India abha.sharma@niperraebareli.edu.in.
- Department of Pharmacology and Toxicology/Regulatory Toxicology, National Institute of Pharmaceutical Education and Research Raebareli Transit Campus Lucknow Uttar Pradesh India.
ORCID-Profile: Saba Naqvi, Abha Sharma
Zitieren
APA
Rajamani, G., Naqvi, S., & Sharma, A. (2026). Structure–activity relationship of GSK-3β inhibitors: insight into drug design for Alzheimer's disease. RSC Medicinal Chemistry, 17(1), 15-51. https://doi.org/10.1039/d5md00211g
Vancouver
Rajamani G, Naqvi S, Sharma A. Structure–activity relationship of GSK-3β inhibitors: insight into drug design for Alzheimer's disease. RSC Medicinal Chemistry. 2026;17(1):15-51. doi:10.1039/d5md00211g
BibTeX
@article{Rajamani2026,
author = {Rajamani, G and Naqvi, Saba and Sharma, Abha},
title = {Structure–activity relationship of GSK-3β inhibitors: insight into drug design for Alzheimer's disease},
journal = {RSC Medicinal Chemistry},
year = {2026},
volume = {17},
number = {1},
pages = {15--51},
doi = {10.1039/d5md00211g}
}
EUVIMED